Skip to main content
Premium Trial:

Request an Annual Quote

Wylie Chenn, Greg Lucier, Qiagen

Premium

Migrations

Serologicals has named Wylie Chenn as regional director for the Asia/Pacific region, the company said last week.

Chenn was most recently general manager, bioscience division for the Asia/Pacific region for Fisher Scientific. He received a BS in marketing and international business from Brigham Young University and an MBA from the University of Washington.


Invitrogen President and CEO Greg Lucier has become a member of the board of trustees of the Burnham Institute, the La Jolla, Calif.-based institute said last week.

 

Products

Qiagen last week announced the launch of its Human Druggable Genome siRNA Set V2.0. It made the first delivery of the product to the Scripps Research Institute in Florida.

The new Druggable Genome Set enables gene silencing studies of 6,692 potential human druggable targets, Qiagen said. The siRNAs are designed using Qiagen's HiPerformance siRNA Design Algorithm, which ensures maximum silencing and minimum risk of non-specific events, Qiagen said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.